Gitnux/Report 2026

Global Breast Cancer Statistics

Breast cancer keeps rising in more developed regions even as access gaps in low and middle income countries translate lower incidence into 70% of deaths, and GLOBOCAN 2020 estimates 7.8 million people living with breast cancer after 5 years. You will also see how biomarker subtypes and prevention choices reshape outcomes, from the 42% mortality drop in the US to the 20% relative reduction in deaths from screening mammography.
38Statistics
20Sources
10Sections
8mRead
May 14, 2026Updated
Global Breast Cancer Statistics
Marie LarsenWritten by Marie Larsen·Edited by Elena Vasquez·Fact-checked by Nikolas Papadopoulos
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days
Breast cancer affects millions, but the patterns are anything but uniform. A global 5 year prevalence of about 7.8 million cases in 2020 sits alongside stark geography differences in incidence, and nearly 70% of deaths in LMICs occur despite lower incidence. We piece together what this means for screening, risk factors, and treatments, from HER2 positivity rates to the survival benefits seen in large trials.

Key Takeaways

  • In the IARC GLOBOCAN analysis, breast cancer incidence rate differs by geography with higher rates in more developed regions
  • In LMICs, 70% of deaths occur despite lower incidence, reflecting access and stage at diagnosis issues (WHO summary statistic)
  • The 2017 Global Cancer Observatory estimates show breast cancer is the leading cause of cancer death among women globally
  • In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)
  • In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases
  • Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)
  • In the EU27, about 128,000 breast cancer deaths were estimated for 2020
  • HER2-positive breast cancer accounts for about 15%–20% of cases
  • The USPSTF recommends against routine breast cancer screening for women aged 75 years and older
  • WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk
  • WHO estimates that obesity increases risk of post-menopausal breast cancer
  • The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)
  • The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)
  • The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)
  • 685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)

Breast cancer affects millions worldwide and survival improves with access to screening, targeted therapies, and timely diagnosis.

Related reading

02 · Category

Cost Analysis7 stats

01
In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)[5]
02
In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases[1]
03
Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)[6]
04
In the US, the average cost per mammography screening exam is about $250-$300 (market prices vary; estimate in health economic sources)[6]
05
A cost-effectiveness analysis found that adjuvant trastuzumab in HER2-positive early breast cancer has an incremental cost-effectiveness ratio (ICER) in the range of about $20,000–$30,000 per QALY in one modeled setting (reported in economic evaluation)[6]
06
A cost-effectiveness study estimated that mammography screening in average-risk women yields costs per QALY generally within accepted thresholds (modeled ICER reported)[6]
07
In the Global Burden of Disease 2019 study, breast cancer accounted for 3.6 million DALYs in 2019 worldwide (IHME)[7]
Interpretation

Cost Analysis Interpretation

From a cost analysis standpoint, the scale is massive and ongoing as breast cancer is linked to 3.6 million DALYs worldwide in 2019 and around 7.8 million cases over 5 years globally in 2020, yet key interventions and screening tools can still fall in commonly accepted cost effectiveness ranges such as trastuzumab with an ICER of about $20,000 to $30,000 per QALY.

03 · Category

Global Incidence1 stats

01
In the EU27, about 128,000 breast cancer deaths were estimated for 2020[8]
Interpretation

Global Incidence Interpretation

Under the Global Incidence framing, the estimated 128,000 breast cancer deaths in the EU27 in 2020 underscore how this disease continues to drive significant mortality at a population level worldwide.

04 · Category

Mortality & Survival1 stats

01
HER2-positive breast cancer accounts for about 15%–20% of cases[6]
Interpretation

Mortality & Survival Interpretation

From a Mortality and Survival perspective, HER2-positive breast cancer makes up about 15% to 20% of cases, underscoring that a significant share of patients could meaningfully influence overall survival outcomes.

05 · Category

Risk & Screening4 stats

01
The USPSTF recommends against routine breast cancer screening for women aged 75 years and older[9]
02
WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk[2]
03
WHO estimates that obesity increases risk of post-menopausal breast cancer[2]
04
A meta-analysis reported that screening mammography reduces breast cancer death by 20% in older women (aged 50+), relative to unscreened controls[6]
Interpretation

Risk & Screening Interpretation

For Risk & Screening, the key takeaway is that even small differences in screening and lifestyle matter, since screening mammography can cut breast cancer deaths by 20% in women aged 50 and older while WHO notes that alcohol and obesity increase risk, and the USPSTF recommends against routine screening for women 75 and older.

More related reading

06 · Category

Market Size6 stats

01
The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)[10]
02
The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)[11]
03
The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)[12]
04
The global breast cancer screening market is projected to reach $4.8 billion by 2030 (Precedence Research forecast)[13]
05
The global breast cancer immunotherapy market size was $2.1 billion in 2022 (as stated on publisher market report page)[14]
06
The global mammography systems market is projected to reach about $5.6 billion by 2030 (iMARC forecast)[15]
Interpretation

Market Size Interpretation

For the market size angle, the breast cancer sector is expanding rapidly, with therapeutics alone rising to a forecast $32.6 billion by 2030 after reaching $20.8 billion in 2023, while related segments like screening are also projected to grow to $4.8 billion by 2030.

07 · Category

Epidemiology2 stats

01
685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)[1]
02
About 1 in 8 women in the US (12.5%) will develop invasive breast cancer over their lifetime (ACS)[16]
Interpretation

Epidemiology Interpretation

Epidemiology data show that breast cancer remains a major health burden, with 685,000 estimated deaths in the European Union in 2020 and about 1 in 8 US women expected to develop invasive breast cancer over their lifetime.

08 · Category

Survivorship1 stats

01
In England, breast cancer is the most common cancer among women, accounting for 15% of all female cancers (Cancer Research UK, 2021)[17]
Interpretation

Survivorship Interpretation

In England, breast cancer being the most common cancer among women at 15% of all female cancers underscores how central survivorship is for a large share of women’s cancer experiences.

09 · Category

Treatment & Outcomes5 stats

01
Trastuzumab can reduce the risk of recurrence by about 30% in HER2-positive early breast cancer when added to adjuvant chemotherapy (HERA trial results)[18]
02
Adjuvant tamoxifen therapy reduces recurrence risk by about 47% versus placebo in early breast cancer (EBCTCG 2011)[19]
03
Adjuvant aromatase inhibitors reduce recurrence risk by about 15% compared with tamoxifen in postmenopausal early breast cancer (EBCTCG 2015)[19]
04
For HER2-positive early breast cancer, adding pertuzumab to trastuzumab plus chemotherapy reduced the risk of invasive disease recurrence or death by 44% (APHINITY trial)[20]
05
Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF)-based regimens increased survival benefit by reducing breast cancer recurrence when compared with no systemic therapy (EBCTCG overview, meta-analysis)[19]
Interpretation

Treatment & Outcomes Interpretation

Overall, Treatment & Outcomes advances are showing that adding the right systemic therapy can sharply improve breast cancer outcomes, with recurrence risk reductions ranging from about 15% for aromatase inhibitors versus tamoxifen to about 44% for pertuzumab added to trastuzumab in HER2-positive disease.

10 · Category

Market & Investment2 stats

01
The global breast cancer immunotherapy market was valued at $2.1 billion in 2022 (industry report estimate)[14]
02
Breast cancer molecular testing volumes are expanding, with the global breast cancer diagnostics market expected to exceed $10 billion by 2030 (forecast)[15]
Interpretation

Market & Investment Interpretation

In the Market and Investment landscape, breast cancer is attracting growing capital as the immunotherapy market reached $2.1 billion in 2022 and diagnostics are forecast to top $10 billion by 2030.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Marie Larsen. (2026, February 13). Global Breast Cancer Statistics. Gitnux. https://gitnux.org/global-breast-cancer-statistics
MLA
Marie Larsen. "Global Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-breast-cancer-statistics.
Chicago
Marie Larsen. 2026. "Global Breast Cancer Statistics." Gitnux. https://gitnux.org/global-breast-cancer-statistics.

Sources & references

20 sources cited across this report

  1. gco.iarc.fr
  2. who.int
  3. cochranelibrary.com
  4. academic.oup.com
  5. seer.cancer.gov
  6. ncbi.nlm.nih.gov
  7. ghdx.healthdata.org
  8. ec.europa.eu
  9. uspreventiveservicestaskforce.org
  10. researchandmarkets.com
  11. marketsandmarkets.com
  12. grandviewresearch.com
  13. precedenceresearch.com
  14. fortunebusinessinsights.com
  15. imarcgroup.com
  16. cancer.org
  17. cancerresearchuk.org
  18. pubmed.ncbi.nlm.nih.gov
  19. thelancet.com
  20. nejm.org